Globus Medical (GMED) to Release Earnings on Thursday

Globus Medical (NYSE:GMED) will likely be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $740.3410 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. The firm had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business’s revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business posted $0.84 EPS. On average, analysts expect Globus Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Globus Medical Price Performance

Shares of GMED traded up $0.27 during trading hours on Wednesday, hitting $90.30. The stock had a trading volume of 272,474 shares, compared to its average volume of 1,188,658. The firm has a 50 day simple moving average of $90.08 and a 200-day simple moving average of $86.26. The firm has a market capitalization of $12.21 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 2.12 and a beta of 1.00. Globus Medical has a 1-year low of $51.79 and a 1-year high of $101.40.

Analyst Upgrades and Downgrades

GMED has been the subject of several research reports. Wells Fargo & Company upgraded Globus Medical to a “strong-buy” rating in a research note on Wednesday, March 18th. Needham & Company LLC raised their price target on shares of Globus Medical from $112.00 to $114.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.36.

Insiders Place Their Bets

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of institutional investors and hedge funds have recently made changes to their positions in GMED. Invesco Ltd. lifted its holdings in Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares in the last quarter. Corient Private Wealth LLC raised its position in Globus Medical by 87.4% during the fourth quarter. Corient Private Wealth LLC now owns 89,916 shares of the medical device company’s stock worth $7,851,000 after acquiring an additional 41,934 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Globus Medical in the fourth quarter valued at about $499,000. EP Wealth Advisors LLC purchased a new stake in shares of Globus Medical in the fourth quarter valued at about $607,000. Finally, Fuller & Thaler Asset Management Inc. purchased a new position in Globus Medical during the fourth quarter worth about $90,411,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.